Steven Goldman, MD, is Professor of Medicine at the UA Sarver Heart Center. A native of Ohio, he received his undergraduate education at Cornell University and his Medical Doctorate from The University of Cincinnati Medical School. His residency training was at The University of Illinois, The University of Chicago and Stanford University. He received his cardiology training at the Pacific Medical Center in San Francisco, California. He came to The University of Arizona in 1975 from California. He was Chief of Cardiology at the Southern Arizona VA Health System and now is full time at the University of Arizona Sarver Heart Center.
Dr. Goldman has won numerous awards for teaching over the years. In 2008, Dr. Goldman was named the Founders Day Speaker at the University of Arizona College of Medicine - Tucson. This award is given each year to a faculty member with a long successful research career at the University of Arizona. In 2010, he was awarded the Charles W. Hall, Jr. Memorial Cardiology Fellowship Teaching Award. His research laboratory has received funding from the Sarver Heart Center, the Tech Launch Arizona, the Veterans Administration, National Institutes of Health, American Heart Association, the Arizona Biomedical Research Commission, the biotechnology industry, and private foundations. His laboratory has supported the development of several young investigators.
Dr. Goldman’s clinical research has focused on graft patency (evaluating the openness of arteries) after coronary artery bypass grafting (CABG). He has been the principle investigator and co-investigator on a number of large VA multicenter studies that defined the appropriate use of aspirin for vein graft patency after CABG. He is currently completing a long-term trial defining radial artery graft patency after CABG.
Dr. Goldman’s work in the laboratory focuses on cardiovascular physiology and pharmacology. To this end, he has been investigating cell-based therapy for heart failure using stem cells seeded on a biodegradable patch as treatment for heart failure. He and Jordan Lancaster, PhD, founded Avery Therapeutics, a biotechnology start-up company that is a spin off from the University of Arizona to commercialize this idea.